News
Patient-reported outcomes could have a prognostic and predictive impact on care for multiple myeloma.A retrospective analysis ...
STOBOCLO ® (denosumab-bmwo) and OSENVELT ® (denosumab-bmwo) are approved by FDA for all indications of PROLIA ® (denosumab) and XGEVA ® (denosumab) respectively [1], [2] STOBOCLO and OSENVELT, among ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results